Table 1.
Basic characterisation of total COVID-19 patients’ cohort and cohort selected for the lymphocyte analysis.
| Parameter | Normal value | Total sample N= 342; Me (Q1-Q3) | Immunophenotyped sample N= 43; Me (Q1-Q3) |
|---|---|---|---|
| Age, years | 59,00 (48,0- 67,0) | 60,0 (50,0-69,0) | |
| Hospitalization, days | 12,00 (10,0-14,0) | 9,0 (8,0-12,0) | |
| Before hospitalization, days | 7,00 (5,0-9,0) | 7,0 (5,0-10,0) | |
| Leukocytes, 1 * 106 / l | 4,0-9,0 | 5,10 (3,7-7,0) | 4,84 (4,02-6,75) |
| Platelets, 1* 103 / l | 150-400 | 195,0 (157,0-252,0) | 180,0 (143,0-229,0) |
| Erythrocytes, 1 * 1012 / l | 3,5-5,5 | 4,6 (4,26-4,88) | 4,48 (4,18-4,72) |
| Neutrophils, % | 40-70 | 71,4 (61,2-78,4) | 62,5 (54,8-73,5) |
| Lymphocytes, % | 19-45 | 23,2 (15,7-31,7) | 24,0 (19,5-34,3) |
| Neutrophils / Lymphocytes ratio | 2,47±0,65 | 3,08 (1,89-4,84) | 2,58 (1,64-3,68) |
| CRP, mg / l | 0-9 | 44,9 (24,4-73,7) | 29,6 (18,0-60,0) |
| Creatinine, μmol / l | 44-124 | 91,7 (83,0-104,0) | 95,6 (80,2-105,5) |
| AST, Unit | 2-35 | 29,4 (22,3-42,2) | 25,6 (20,4-34,8) |
| ALT, Unit | 4-41 | 26,5 (18,6-43,3) | 26,5 (18,1-33,8) |
| KFK, Ed | 2-171 | 122,5 (70,0-234,0) | 111,0 (73,0-163,0) |
| LDH, Unit | 5-480 | 360,0 (301,0-449,0) | 323,0 (264,0-430,0) |
| Iron, μmol / l | 6,6 - 26 | 8,0 (5,2-12,2) | 11,0 (6,1-17,0) |
| Ferritin, mcg / l | 20 - 250 | 380,2 (188,1-631,4) | 287,0 (156,05-540,5) |
AST, aspartate aminotransferase; ALT, alanine aminotransferase; KFK, creatine phosphokinase; LDH, lactate dehydrogenase.